Last reviewed · How we verify
Angde Biotech Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Recombinant human tissue plasminogen activator | Recombinant human tissue plasminogen activator | phase 3 | Fibrinolytic agent / Thrombolytic | Plasminogen / Fibrin | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- All India Institute of Medical Sciences · 1 shared drug class
- Beijing Chao Yang Hospital · 1 shared drug class
- Beijing Tiantan Hospital · 1 shared drug class
- Life Recovery Systems · 1 shared drug class
- Tasly Biopharmaceuticals Co., Ltd. · 1 shared drug class
- The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class
- Thrombolex, Inc. · 1 shared drug class
- Tianjin Huanhu Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Angde Biotech Pharmaceutical Co., Ltd.:
- Angde Biotech Pharmaceutical Co., Ltd. pipeline updates — RSS
- Angde Biotech Pharmaceutical Co., Ltd. pipeline updates — Atom
- Angde Biotech Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Angde Biotech Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/angde-biotech-pharmaceutical-co-ltd. Accessed 2026-05-16.